Meta-analysis showing that ERCC1 polymorphism is predictive of osteosarcoma prognosis

Abstract

To investigate correlations between excision repair cross-complementation group 1 (ERCC1) and 2 (ERCC2) polymorphisms and osteosarcoma prognosis, we conducted a meta-analysis of studies published through October 2016. Studies were identified in the PubMed, ScienceDirect, Springer, and Web of Science databases using preferred reporting items for systematic reviews and meta-analyses (PRISMA). Odds ratios (ORs) or hazard ratios (HRs) and their 95% confidence intervals (CIs) for overall survival (OS), tumor response (TR), and event-free survival (EFS) were estimated. Our meta-analysis included eleven studies in which four SNPs (ERCC1 rs11615 and rs3212986, ERCC2 rs13181 and rs1799793) reportedly associated with osteosarcoma prognosis were investigated. Each of these studies scored > 6 on the Newcastle-Ottawa Scale (NOS). We found that only one SNP, ERCC1 rs11615, correlated with improved OS and TR. The HR of T vs. C for OS was 1.455 (T/C, 95% CI = 1.151–1.839, P = 0.002, I2 = 37.80%). The OR of T vs. C for good TR was 0.554 (T/C, 95% CI = 0.437–0.702, P < 0.001, I2 = 0%). Few significant outcome was observed in subgroup analyses stratified based on study characteristics with adjustments for potential confounders. Our results suggest that ERCC1 rs11615 CC is associated with a better clinical outcome. This suggests rs11615 may be a useful genetic marker for predicting osteosarcoma prognosis.

Diagnostic and prognostic values of the mRNA expression of excision repair cross-complementation enzymes in hepatitis B virus-related hepatocellular carcinoma

“…An investigation carried out by Liu et al revealed the fact that ERCC1 -rs11615 is likely to be a useful genetic marker for the prediction of the osteosarcoma prognosis and that the CC genotype is correlated with a better clinical outcome. 46 The work performed by Liu et al indicated that the XRCC1- 399A/A genotype was significantly correlated with a better clinical outcome. 47 Previous studies demonstrated that genetic variants of ERCC2 and ERCC5 may be the independent prognostic factors in the patients with melanoma 32 , 48 and osteosarcoma.…”

The effect of ERCC1 and ERCC2 gene polymorphysims on response to cisplatin based therapy in osteosarcoma patients

“…Many studies have investigated the potential predictive and prognostic role of ERCC1 (C118T and C8092A) and ERCC2 (A751C and G312A) genetic polymorphisms on either tumors’ response to cisplatin chemotherapy or clinical outcomes [ 14 , 17 , 19 – 23 ]. Of these studies, many have shown significant associations with some of these variants, but others still revealed contradictory outcomes.…”

“…Excision repair cross-complementing 1 (ERCC1) and excision repair cross-complementing 2 (ERCC2) are major members in NER pathway [ 16 ]. Many single nucleotide polymorphisms have been identified in ERCC1 and ERCC2 genes; of these polymorphisms, ERCC1 (C118T & C8092A) and ERCC2 (A751C & G312A) have been shown to affect the repair capacity and concomitantly the tumor’s sensitivity to cisplatin [ 17 , 18 ].…”

Genomics and Therapeutic Vulnerabilities of Primary Bone Tumors

“…Concerning DNA repair, the most consistent data have been reported for polymorphisms of the excision repair 1 (ERCC1) and excision repair 2 (ERCC2) genes, both involved in the nucleotide excision repair (NER) pathway. Although findings have sometimes been contradictory, two meta-analyses indicated that HGOS patients carrying the C allele of ERCC1 rs11615 [16,17] or the A allele of ERCC2 rs1799793 [17] have higher probabilities of responding to conventional chemotherapy among Chinese populations. Among genes related to methotrexate metabolism, the most widely studied in HGOS has been the 5,10-methylenetetrahydrofolate reductase (MTHFR) [15,18].…”